Affimed N.V. announced interim safety and efficacy data on its innate cell engager (ICE(R) AFM24 from the ongoing AFM24-102 combination study with atezolizumab, an anti-PD-L1 checkpoint inhibitor, in patients with advanced EGFR-expressing solid tumors. The data update as of December 6(th), 2023, includes 15 patients from the EGFR- wildtype NSCLC cohort with a median of 2 prior lines of therapy. The Company also announced data from the phase 1/2 data study of acimtamig in combination with allogeneic NK in relapsed/refractory Hodgkin Lymphoma patients conducted at the University of Texas MD Anderson Cancer Center.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
5.36 USD | +6.56% | +7.00% | -14.40% |
Apr. 01 | Wells Fargo Cuts Affimed Price Target to $25 From $30, Maintains Overweight Rating | MT |
Apr. 01 | HC Wainwright Adjusts Affimed's Price Target to $10 From $50, Maintains Buy Rating | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-14.40% | 76.59M | |
-2.49% | 103B | |
+1.84% | 95.28B | |
+1.46% | 22.15B | |
-15.61% | 21.02B | |
-8.58% | 18.15B | |
-38.74% | 16.73B | |
-13.05% | 16.05B | |
+5.39% | 13.68B | |
+34.86% | 12.17B |
- Stock Market
- Equities
- AFMD Stock
- News Affimed N.V.
- Affimed N.V. Announces Positive Data for AFM24 in Combination with the PD-L1 Checkpoint Inhibitor Atezolizumab in Heavily Pre-Treated EGFR-Wildtype Non-Small Cell Lung Cancer Patients